Abstract
Adoptive cell therapy (ACT) using tumor-infiltrating lymphocytes (TILs) has shown clinical responses in the treatment of metastatic melanoma. Improvement in the persistence of TILs is an area of ongoing investigation. Emerging data has demonstrated that levels of circulating metabolites significantly affect T cell function and survival in multiple pre-clinical models of ACT. However few studies have interrogated the circulating metabolome in patients undergoing ACT. We aimed to investigate changes in the serum metabolome in patients with metastatic melanoma undergoing ACT with TILs.
Full Text
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call